Oncology experts at PCOC 2025 discuss breakthrough therapies, AI-driven care, and evolving care delivery models shaping the future of oncology.
Vivek Subbiah, MD
Advertisement
Vivek Subbiah, MD, is the chief of early-phase drug development at Sarah Cannon Research Institute.
Articles by Vivek Subbiah, MD
Vivek Subbiah, MD, highlights key topics at the 50th European Society for Medical Oncology (ESMO) Congress, including the rise of tumor-agnostic therapies and the use of artificial intelligence (AI) in cancer care.
Vivek Subbiah, MD, says artificial intelligence (AI) should assist clinicians in precision oncology, not replace human decision-making.
Artificial intelligence (AI) is expanding clinical trial access and enabling drug repurposing, according to Vivek Subbiah, MD.
Five experts share their key takeaways from Patient-Centered Oncology Care® (PCOC) 2025, highlighting AI integration and collaboration to improve care.
Vivek Subbiah, MD, considers artificial intelligence (AI) and comprehensive somatic and germline testing essential for guiding precision oncology and improving patient care.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
3
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
4
Study Finds Flaw in Method for Key Oncology Value-Based Care Model
5